Fan Yahui, Wang Mingxu, Li Zhaofang, Jiang Hong, Shi Jia, Shi Xin, Liu Sijiao, Zhao Jinping, Kong Liyun, Zhang Wei, Ma Le
The First Affiliated Hospital, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, China.
Front Nutr. 2022 Mar 4;9:847421. doi: 10.3389/fnut.2022.847421. eCollection 2022.
Associations between soy intake and risk of cancer have been evaluated in prospective observational studies with inconsistent results. Whether the potential anticancer effects offered by soy were attributed to soy isoflavones and soy protein still needs to be elucidated. This study aimed to comprehensively quantify the association of soy, soy isoflavones and soy protein intake with risk of cancer incidence and cancer mortality by conducting a meta-analysis of all available studies.
PubMed, Embase, Web of Science, and Cochrane Library databases were searched up to 16 September 2021. Prospective cohort studies that examined the effect of soy, soy isoflavones and soy protein on cancer incidence and cancer mortality were identified. Random-effects models were used to pool the multivariable-adjusted relative risks (RRs) and corresponding 95% confidence intervals (CIs). The potential dose-response relations were explored by using generalized least-squares trend estimation.
Eighty one prospective cohort studies were included in the meta-analysis. A higher intake of soy was significantly associated with a 10% reduced risk of cancer incidence (RR, 0.90; 95% CI, 0.83-0.96). Each additional 25 g/d soy intake decreased the risk of cancer incidence by 4%. Intake of soy isoflavones was inversely associated with risk of cancer incidence (RR, 0.94; 95% CI, 0.89-0.99), whereas no significant association was observed for soy protein. The risk of cancer incidence was reduced by 4% with each 10 mg/d increment of soy isoflavones intake. Similar inverse associations were also found for soy in relation to site-specific cancers, particularly lung cancer (RR, 0.67; 95%CI, 0.52-0.86) and prostate cancer (RR, 0.88; 95%CI, 0.78-0.99). However, high intake of soy, soy isoflavones and soy protein were not associated with cancer mortality.
Higher intake of soy and soy isoflavones were inversely associated with risk of cancer incidence, which suggested that the beneficial role of soy against cancer might be primarily attributed to soy isoflavones. These findings support recommendations to include soy as part of a healthy dietary pattern for the prevention of cancer.
前瞻性观察性研究对大豆摄入量与癌症风险之间的关联进行了评估,但结果并不一致。大豆所具有的潜在抗癌作用是否归因于大豆异黄酮和大豆蛋白仍有待阐明。本研究旨在通过对所有现有研究进行荟萃分析,全面量化大豆、大豆异黄酮和大豆蛋白摄入量与癌症发病率及癌症死亡率风险之间的关联。
检索截至2021年9月16日的PubMed、Embase、Web of Science和Cochrane图书馆数据库。纳入考察大豆、大豆异黄酮和大豆蛋白对癌症发病率及癌症死亡率影响的前瞻性队列研究。采用随机效应模型汇总多变量调整后的相对风险(RR)及相应的95%置信区间(CI)。通过广义最小二乘趋势估计探索潜在的剂量反应关系。
荟萃分析纳入了81项前瞻性队列研究。大豆摄入量较高与癌症发病率风险降低10%显著相关(RR = 0.90;95%CI:0.83 - 0.96)。大豆摄入量每增加25克/天,癌症发病率风险降低4%。大豆异黄酮摄入量与癌症发病率风险呈负相关(RR = 0.94;95%CI:0.89 - 0.99),而大豆蛋白未观察到显著关联。大豆异黄酮摄入量每增加10毫克/天,癌症发病率风险降低4%。大豆与特定部位癌症,尤其是肺癌(RR = 0.67;95%CI:0.52 - 0.86)和前列腺癌(RR = 0.88;95%CI:0.78 - 0.99)之间也发现了类似的负相关。然而,大豆、大豆异黄酮和大豆蛋白的高摄入量与癌症死亡率无关。
大豆和大豆异黄酮的较高摄入量与癌症发病率风险呈负相关,这表明大豆对癌症的有益作用可能主要归因于大豆异黄酮。这些发现支持将大豆纳入预防癌症的健康饮食模式的建议。